Argenx readies a blockbuster opportunity with drug for autoimmune disease

Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

advertisement

Read on for brief explanations of what we’re watching for from each company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!